Open | 0.95 |
Previous Close | 0.903 |
Day Range | 0.94 - 0.95 |
52-Week Range | 0.82 - 3.92 |
All-Time High | 53.01 |
Avg. Volume (50-day) | 47,954 |
EPS (TTM) | -1.3463 |
Next Earnings Date | - |
Last Earnings Date | - |
Forward Annual Dividend (Yield) | - |
Trailing Annual Dividend (Yield) | - |
Options | No |
P/E Ratio | -0.6700 |
PEG Ratio | -0.37 |
Price to Book | 0.94 |
Price to Cash Flow | - |
Price to Free Cash Flow | - |
Total Sales (TTM) | - |
Revenue per Share (TTM) | - |
Shares Outstanding | 3.481 M |
Share Float (%) | 3.35 M |
% Held by Institutions | 8.24 |
Dividends Per Share (TTM) | - |
Ex-Dividend Date | - |
+/- EMA(20) | 0.96 (-1.04%) |
+/- SMA(50) | 0.94 (+1.06%) |
+/- SMA(200) | 1.4 (-32.14%) |
5-Day Perf. | - |
1-Month Perf. | -3.04% |
3-Month Perf. | -18.8% |
6-Month Perf. | -38.39% |
YTD Perf. | -15.9% |
1-Year Perf. | -71.85% |
RSI(14) | 43.97 |
ATR(14) | 0.09 |
ADX(14) | 38.29 |
Beta (5Y) | 0.39 |
As a StockCharts Member, you can review earnings results and analyze revenue and earnings growth over time. Bring a balance of technicals and fundamentals to your approach when you join today!
XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm engages in development and commercialization of innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.
XRTX has triggered the following predefined scans:
No Recent Scan Appearances |
As a StockCharts Member, you can create your own unique alerts with the technical criteria that matters most to you. Stay ahead of important moves and never miss a thing in the markets.
As a StockCharts Member, you can save the charts you're watching to your own account with ChartLists. Accessible from any device, you can organize, review and analyze your charts on-the-go, anytime, anywhere.